Cellular Biomedicine Group Inc. , a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced that Dr. William Cao, Chief Executive Officer of the Company, will present "48-week Clinical Results from Phase IIa Trial of Human Adipose Mesenchymal Progenitor Cell Treatment for Knee Osteoarthritis" at the 10th Annual World Stem Cell Summit and RegMed Capital Conference held at the Marriott Rivercenter, San Antonio, Texas, December 3-5, 2014. "We look forward to discussing the data analysis comprising of WOMAC, NRS-11, SF-36 and KSCRS indices.
http://ift.tt/1FoXzsz
http://ift.tt/1FoXzsz
No comments:
Post a Comment